Spots Global Cancer Trial Database for A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
Official Title: A Phase Ib/II Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
Study ID: NCT03571308
Conditions
Interventions
Study Description
Brief Summary: Previously untreated CD20 positive diffuse large B-cell lymphoma (DLBCL) requiring full course chemoimmunotherapy.
Detailed Description: Open-label non-randomised phase Ib/II study conducted in two stages. Stage 1 will be dose escalation in a modified classical 6+6 design. Stage 2 will be an expansion cohort to gain additional information on safety and efficacy at the recommended phase II dose of acalabrutinib.
Eligibility
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Southampton University Hospitals NHS Tust, Southampton, Hampshire, United Kingdom
St James's University Hospital, Leeds, , United Kingdom
University College London Hospitals, London, , United Kingdom
The Christie NHS Foundation Trust, Manchester, , United Kingdom
Nottingham City Hospital Campus, Nottingham, , United Kingdom
Churchill Hospital, Oxford, , United Kingdom
Derriford Hospital, Plymouth, , United Kingdom
Contact Details
Name: Andy Davies
Affiliation: Southampton University Hospital NHS Foundation Trust
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
